{
  "id": 5889642,
  "title": "Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?",
  "url": "https://urgent.news/2026/09/04/wall-street-has-cooled-on-moderna-after-its-stock-jumped-over-5x-but-5889642",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T20:15:00.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/wall-street-cooled-moderna-stock-201500584.html"
  },
  "original_language": "en",
  "account": "Moderna (NASDAQ: MRNA) has experienced an incredible surge in its stock price, with the company's shares up 404% this year and a staggering 515% over the past 12 months. At current levels, shares trade around $148, a significant drop from the $176.66 peak earlier this year. While this pullback may raise concerns about the stock's upside potential, the broader perspective tells a different story. Over the past five years, Moderna has lost over 60% of its value, primarily due to the decline in vaccine demand and the belief that its mRNA platform's commercial success beyond COVID-19 wouldn't be as significant. However, recent positive developments suggest that Moderna's prospects remain strong. The company's Phase 3 clinical trial results for intismeran autogene, an investigational personalized mRNA-based cancer vaccine, show promising results in melanoma patients when combined with Merck's Keytruda. This success could pave the way for approval and generate significant revenue. Furthermore, intismeran autogene is being explored for other cancers, including lung, bladder, and kidney, which could further boost Moderna's pipeline value. The flu vaccine mFLUSIVA, which outperformed some approved vaccines in phase 3 studies, also adds to Moderna's revenue potential. Analysts estimate that intismeran autogene could generate $5.6 billion in peak revenue, which Moderna will share with Merck. While the stock's current valuation, with a price-to-sales ratio of 27.5, may appear expensive for a company without revenue or profit, the long-term outlook remains positive. Moderna's pipeline is filled with promising mRNA-based candidates across various therapeutic areas, including challenging targets. With potential approval of intismeran autogene and other candidates, coupled with a stabilizing revenue stream in the medium term, Moderna could emerge as a well-established mRNA leader within five years.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?",
        "url": "https://urgent.news/2026/09/04/wall-street-has-cooled-on-moderna-after-its-stock-jumped-over-5x-but",
        "published": "2026-09-04T19:55:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}